Leukocytes from patients with leukemia and L1210 cells from mice were examined for the rate offormation and cellular concentration of phosphoribosylpyrophosphate, the rate of thioinosinic acid formation, and a number of selected enzymes involved in purine nucleotide synthesis. The amount of thioinosinic acid formed in L1210 cells was much higher than that in human leukemic leukocytes. In cell extracts, the synthesis of thioinosinic acid was similar in both cell types, and the amount of purine phosphoribosyltransferase was not rate limiting in either case. Much higher concentrations and rates of formation of phosphoribosylpyrophosphate were found in L1210 cells than in human leukemic leukocytes. The difference in response to 6-mercaptopurine between L1210 cells and human leukemic leukocytes might be attributed to their difference in supply of phosphoribosylpyrophosphate. Phosphoribosylpyrophosphate-amidotransferase was found to be high in L1210 cells, but was not detected in human leukemic leukocytes.
transferase was found to be high in L1210 cells, but was not detected in human leukemic leukocytes.
The enzymes responsible for purine nucleotide synthesis have been only partially studied in L1210 cells (4, 26) . Few studies have been done on the characterization of the enzymes that are essential to the mechanism of action of 6-mercaptopurine (6-MP) in humans (5, 19, 20) . It is well known that nucleotides can be formed by means of a de novo pathway from single metabolites or, alternatively, synthesized from preformed purine bases by means of salvage pathways. Synthesis ofpurine nucleotides from preformed purines in cells has been shown to be controlled more extensively by the endogenous supply of phosphoribosylpyrophosphate (PRPP) than by the activity of the purine phosphoribosyltransferase in experimental animal tumor cells (7) , human erythrocytes (24) , and lymphoblasts (6) . To study the regulation of purine nucleotide synthesis and to clarify the mechanism of action of 6-MP in humans, we have undertaken comparative studies on the salvage and de novo pathways, the cellular concentration of PRPP, and the enzymes responsible for PRPP formation in human leukemic leukocytes and L1210 cells. been given 6-MP during the preceding month. Blood was drawn by venipuncture into heparinized tubes. The plasma and buffy coat were separated by centrifugation in the cold and then removed. Sedimented erythrocytes were washed twice with cold, 0.9% NaCl solution.
Isolation of leukocytes. Leukocytes were isolated from peripheral blood by the dextran sedimentation procedure (23) . The cells were mixed with 1 volume of 3% dextran in 0.9% NaCl solution and allowed to sediment at room temperature for 30 to 45 min until a good separation was noted. The supernatant containing leukocytes, platelets, and some erythrocytes was decanted into a test tube in which all subsequent steps were performed. The cells were sedimented at 500 x g for 10 min, washed with 0.9% NaCl solution, and sedimented at 500 x g for 10 min. The cells were suspended in 0.9% NaCl solution and sedimented as described above. The leukocyte pellet was suspended in 1 ml of 0.9% NaCl solution. Contaminating erythrocytes were lysed by adding 3 volumes of water at 0°C. After 40 s, isotonicity was restored by adding 1 volume of 3.6% NaCl solution. The unbroken cells were collected by centrifugation at 500 x g for 10 min, washed twice with 0.9% NaCl solution, resuspended, and centrifuged.
Isolation of L1210 cells. L1210 cells, harvested from mice 7 days after interperitoneal inoculation of 3 x 10" cells, were washed twice with 0.9% NaCl solution. Erythrocytes were removed by lysis with hypotonic NaCl solution as described above.
Determination of thioinosinic acid (TIMP) formation. The leukocytes or L1210 cells were suspended in Eagle minimum essential medium containing 3G% calf serum in a concentration of 3 x 107 cells per ml. The cell suspension (final volume, 10 ml) was incubated at 37°C for 60 min in the presence of 0.05 -,umol of 6 [8-14C] MP. At the end of the incubation the mixture was chilled in an ice bath, and the cells were collected by centrifugation and washed twice with 1 ml of Eagle minimum essential medium. The acid-soluble fraction was obtained by adding 0.05 ml of 10 M perchloric acid and then centrifuging. The residue was washed again with 1 ml of 0.5 M perchloric acid. The extracts were combined and neutralized with potassium hydroxide. After removal of insoluble perchloric acid, the neutralized extracts were chromatographed on a column of Dowex-1 formate resin (1 by 20 cm) with the appropriate carriers, with a formic acid gradient elution system (0 to 20 N). Column eluates were collected in 5-ml fractions with an automatic fraction collector. Nucleotides formed were determined by measuring the radioactivity of 0.5 ml of each fraction in toluene-based scintillation fluid by a Packard Tri-Carb scintillation counter (Packard Instrument Co., Inc., Rockville, Md.). They are presented as nanomoles formed per 3 x 107 cells per h. Compared with the radioactivity of nucleotides in both human leukemic leukocytes and L1210 cells, little radioactivity was detected in the nucleoside region.
Extraction of PRPP. The sedimented leukocytes or L1210 cells, prepared as described above, were suspended in 1 ml of ethylenediaminetetraacetic acid (EDTA), pH 7.4, at a concentration of 2 x 107 cells per ml. The suspensions were deproteinized by heating in boiling water for 2 min and then promptly chilling in an ice bath. The denatured protein was sedimented by centrifugation, and the clear, supernatant fluid was used immediately for assaying the PRPP content. The recovery test showed that EDTA substantially prevented decomposition of PRPP (<10%) during the 2-min heating.
Assay of PRPP. The PRPP content of leukocytes and L1210 cells was determined by a modification of the procedure of Henderson and Khoo (8) . The reaction mixture contained: 55 ,umol of tris(hydroxymethyl)aminomethane (Tris) buffer (pH 7.4), 5 ,fmol of MgCl2, 10 nmol of [8_'4C]hypoxanthine, 0.09 ml of cell extract, and 0.1 ml of hemolysate (see below) in a final volume of 0.25 ml. After 20 min of incubation at 37°C, the reaction was stopped by adding 2 p.mol ofneutralized EDTA, and a 20-Al portion of the reaction mixture was spotted on Toyo no. 51 paper with appropriate carriers. Inosinic acid that was produced was separated from the substrate by high-voltage electrophoresis by using 0.05 M borate buffer (pH 9.0) containing 0.001 M EDTA at 4,000 V for 20 min (Rf values were: hypoxanthine, 0.03; inosinic acid, 1.00). The radioactivities were determined by cutting the chromatographic paper into 0.5-cm strips and counting them in toluenebased scintillation fluid by a Packard Tri-Carb scintillation counter. The amounts of PRPP in the assay medium were calculated from the amount of inosinic acid produced. The standard curves showed a linear responsiveness of up to . (17) .
Also, synthesis of PRPP during incubation of leukemic leukocytes was determined. Even after incubating leukocytes in Eagle minimum essential medium at 370C for 60 min, the intracellular concentrations of PRPP did not increase to the threshold of the assay procedure. Since Hershko et al. (9) reported that PRPP formation was enhanced by inorganic orthophosphate, we examined its effects on PRPP formation in leukocyte suspensions. After 1 h of incubation in the presence of 60 mM inorganic orthophosphate, there was a marked elevation of the PRPP concentration. The amount of PRPP formed in leukocytes from 10 patients with acute leukemia ranged from 5.2 to 38.0 nmol/3 x 107 cells per h. In contrast, the amount of PRPP formed in L1210 cells was much higher (Table 1) .
It has been demonstrated by Wood and Seegmiller (27) and Holmes et al. (11) that PRPPATase, the enzyme catalyzing the first step of de novo purine synthesis, exhibits allosteric properties and is subject to feedback regulation by purine nucleotide end products. Because of the apparent regulatory importance of this enzyme in de novo purine synthesis, we determined whether leukemic leukocytes or L1210 cells contained it by directly measuring the rate of I I on September 26, 2017 by guest http://aac.asm.org/ PRPP-dependent glutamate production from glutamine. In leukocytes from patients with acute leukemia, little radioactivity was detected in the glutamate region compared with that in L1210 cells. These results agree with those of others who have shown that leukocyte suspensions lack the initial reaction for de novo purine synthesis (21, 22) and that PRPPATase activity is present in all tissues assayed except human leukemic leukocytes. These values agree fairly well with the figures presented by other workers (10, 18) (Table 1) . DISCUSSION Though the varied response of human leukemic leukocytes to 6-MP is well known, L1210 cells are much more sensitive to this agent (1, 2). It is interesting to consider whether these differences in response represent biochemical differences in 6-MP anabolism. Since many workers have reported that the differences in sensitivity of human leukemic leukocytes and L1210 cells may be related to their capacity to synthesize TIMP (14) , one would expect differences in their capacity to convert 6-MP to TIMP. As shown here, TIMP formation was greater in L1210 cells than in leukemic leukocytes. It has been shown recently that the rate ofpurine nucleotide salvage synthesis in cells is limited by the supply of PRPP, the activity of purine nucleotide pyrophosphorylase, and purine base transport into cells (6) .
The activities of purine phosphoribosyltransferase in leukemic leukocytes and L1210 cells studied here were reasonably similar and were not rate limiting. L1210 cells, however, had a considerable amount of PRPP, compared to leukemic leukocytes. Furthermore, the amount of TIMP formed in L1210 cells was also much higher than that formed in leukemic leukocytes. Therefore, it seems probable that the differences in capacity of the cells to convert 6-MP to TIMP may be due to its supply of PRPP. The amount of PRPP in leukemic leukocytes is far below the Km value for PRPP in purine nucleotide synthesis. (20) (Table 1) . It is, therefore, likely that the availability of PRPP may be an important factor in regulation of purine nucleotide synthesis. Although there are some reports on the supply of PRPP in erythrocytes, there is no information regarding the supply of PRPP in human leukemic leukocytes and L1210 cells. The synthesis of PRPP from adenosine 5'-triphosphate and ribose 5-phosphate is considered to be regulated by the availability ofribose 5-phosphate (12) . It has also been shown that glucose 6-phosphate dehydrogenase activity is the key enzyme in hexose monophosphate shunt functioning, through which ribose 5-phosphate is channeled (12) . It is interesting to consider whether the differences in supply of PRPP found here represent biochemical differences in hexose monophosphate shunt in the cell types.
There has been no reported information regarding the direct assay of PRPPATase in human leukemic leukocytes. The present study showed that PRPPAtase activity is found in L1210 cells, but not in human leukemic leukocytes, which agrees with the results of other workers obtained by indirect assay (21, 22) . The difference in PRPPATase activity between the two cell lines is interesting, for it enables us to discuss the antileukemic effect of another antimetabolite, methylthioinosine. This compound is able to inhibit growth of some tumor cells, which might be due to the inhibition of PRPPATase by the methylthioinosine nucleotide. In fact, Luce et al. (16) concluded that methylthioinosine was ineffective as an antileukemic agent in patients with acute leukemia, although this agent was very effective in the treatment of mouse L1210 cell leukemia. The difference in effectiveness might be explained on the basis of PRPPATase activity in the two cell lines.
In nonhuman systems, the most frequent cause of acquired insensitivity to 6-MP has been the loss, or marked decrease, of HGPRTase activity (3). In contrast, to date, a severe deficiency of HGPRTase in 6-MP-resistant human leukemic leukocytes has been reported by Davidson 
